#AUA14 - Multiparametric magnetic resonance imaging and MRI/ultrasound fusion-guided biopsy stratify patients at risk for extracapsular extension at radical prostatectomy - Session Highlights

ORLANDO, FL USA (UroToday.com) - In men with prostate cancer (PCa), the surgical margin status is one of the most important prognostic factors for biochemical recurrence after radical prostatectomy. Pre-operative identification of extracapsular extension (ECE) provides critical information for surgical planning allowing the surgeon to modify the dissection if needed. The reported specificity of multiparametric prostate MRI (MP-MRI) for ECE is high (90%), but the sensitivity is comparably low (58%). Dr. Peter Pinto’s group from the National Cancer Institute conducted a study to evaluate which parameters of MP-MRI and MRI/US fusion-guided biopsy aid in the pre-operative assessment of ECE.

auaThe authors reviewed the records of 370 patients who underwent radical prostatectomy at their institution between May 2007 and March 2014. They identified 116 patients who had pre-operative MP-MRIs suggestive of ECE, and who had MRI/US fusion-guided biopsy and extended sextant 12-core biopsy prior to surgery. The overall prevalence of ECE on final pathology was 23.1%. For the detection of ECE, pre-operative MP-MRI was 48.7% sensitive, 78.9% specific, and had a positive predictive value and negative predictive value of 35.9% and 82.8%, respectively. On multivariate regression analysis, only patient age and targeted biopsy Gleason score were statistically significant predictors of ECE on final pathology when MP-MRI was negative for ECE.

The authors concluded that when MP-MRI fails to detect ECE, MRI/US fusion-guided biopsy, Gleason score, and age are useful pre-operative predictors of ECE on final pathology. This knowledge may guide pre-operative surgical planning and reduce the incidence of positive surgical margins after robotic radical prostatectomy.

Presented by Dima Raskolnikov at the American Urological Association (AUA) Annual Meeting- May 16 - 21, 2014 - Orlando, Florida USA

National Cancer Institute, Bethesda, MD USA

Written by Chinonyerem Okoro, University of California (Irvine), and medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
  • 2020 Virtual Congress / September 19-21
  • 2020 BCAN Think Tank Virtual / August 7
  • 2020 Virtual Education Program / August 8-10
  • 2020 Annual Meeting / July 17-19 / EAU Virtual Program
  • SUO - AUA 2020 Summer Webcast / July 18
  • 2020 Annual Meeting / June 27-28 / AUA Live Virtual Program
  • 2020 Annual Meeting / May 29-31 / Virtual Scientific Program
  • 2020 Annual Meeting / February 13-15 / San Francisco, CA
  • 2019 Annual Meeting / December 4-6 / Washington, DC
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland